Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

Description

This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.

ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA, Los Angeles, California, United States, 90005

San Francisco

UCSF, San Francisco, California, United States, 94143

New York

Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York, United States, 10065

Cleveland

Case Western University Hospitals, Cleveland, Ohio, United States, 44106

Dallas

UT Southwestern, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Males aged ≥ 18.
  • * Histologically confirmed low or favorable intermediate risk prostate cancer per NCCN guidelines. (Note: Grade Group 2 must have 20% or less involvement in every core and no presence of cribiform or intraductal carcinoma).
  • * PSA \< 20 ng/ml.
  • * Ability to undergo yearly PSMA-PET CT.
  • * Ability to undergo yearly prostate mpMRI.
  • * Ability to undergo transrectal or transperineal template and fusion prostate biopsy.
  • * Ability to complete HRQOL surveys (EPIC, IPSS, IIEF-5).
  • * Willingness to undergo yearly prostate biopsies.
  • * History of prior treatment for prostate cancer.
  • * History of systemic therapy for prostate cancer.
  • * Inability to undergo transrectal ultrasound.
  • * Life expectancy less than 10 years.
  • * Not interested in pursuing active surveillance.

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Weill Medical College of Cornell University,

Timothy Mcclure, M.D., PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Himanshu Nagar, M.D., PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

2028-12